华氏巨球蛋白血症

参考文献

关键文献

Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002 Feb 21;346(8):564-9.全文  摘要

McMaster ML. Familial Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:146-152. 摘要

Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenström's macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2004:257-282.全文  摘要

Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 2016 Sep 8;128(10):1321-8.全文  摘要

参考文献

1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375-90.全文  摘要

2. Cesana C, Miqueleiz S, Bernuzzi P, et al. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease. Semin Oncol. 2003;30:231-235. 摘要

3. Merlini G. Waldenstrom's macroglobulinemia - clinical manifestations and prognosis. In: Schechter GP, Hoffman R, Schrier SL, eds. Hematology. Washington, DC: American Society of Hematology; 1999:358-369.

4. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016 Nov 12;66(6):443-59.全文  摘要

5. Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012 Aug 1;118(15):3793-800.全文  摘要

6. Groves FD, Travis LB, Devesa SS, et al. Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer. 1998;82:1078-1081. 摘要

7. Herrinton LJ, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood. 1993;82:3148-3150.全文  摘要

8. Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015 Apr;169(1):81-9.全文  摘要

9. Phekoo KJ, Jack RH, Davies E, et al. The incidence and survival of Waldenstrom's macroglobulinaemia in South East England. Leuk Res. 2008;32:55-59. 摘要

10. Owen RG, Pratt G, Auer RL, et al. Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. Br J Haematol. 2014 May;165(3):316-33.全文  摘要

11. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002 Feb 21;346(8):564-9.全文  摘要

12. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenström's macroglobulinemia. Ann Oncol. 2006;17:488-494.全文  摘要

13. Ogmundsdottir HM, Einarsdottir HK, Steingrimsdottir H, et al. Familial predisposition to monoclonal gammopathy of unknown significance, Waldenstrom's macroglobulinemia, and multiple myeloma. Clin Lymphoma Myeloma. 2009;9:27-29. 摘要

14. McMaster ML. Familial Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:146-152. 摘要

15. Kristinsson SY, Koshiol J, Goldin LR, et al. Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:23-26. 摘要

16. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012 Aug 30;367(9):826-33.全文  摘要

17. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015;372:1430-1440. 摘要

18. Fulciniti M, Amodio N, Bandi RL, et al. MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. Blood. 2014;123:2673-2681. 摘要

19. Roccaro AM, Sacco A, Jimenez C, et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123:4120-4131. 摘要

20. Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123:1637-1646.全文  摘要

21. Treon SP, Hunter ZR. A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Blood. 2013;121:4434-4436.全文  摘要

22. Treon SP, Gustine J, Xu L, et al. MYD88 wild-type Waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018 Feb;180(3):374-80.全文  摘要

23. Sahota SS, Forconi F, Ottensmeier CH, et al. Origins of the malignant clone in typical Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:136-141. 摘要

24. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010-2017. 摘要

25. Leleu X, O'Connor K, Ho AW, et al. Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol. 2007;82:83-84.全文  摘要

26. Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2015 Aug 6;126(6):721-32.全文  摘要

27. Vijay A, Gertz MA. Waldenström macroglobulinemia. Blood. 2007;109:5096-5103.全文  摘要

28. Gertz MA. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019 Feb;94(2):266-76.全文  摘要

29. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30;110-115. 摘要

30. Pangalis GA, Kyrtsonis MC, Kontopidou FN, et al. Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders. Semin Oncol. 2003;30:201-205. 摘要

31. Leleu X, Moreau AS, Weller E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008;49:1104-1107. 摘要

32. Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenström's macroglobulinemia. Leukemia. 2019 Nov;33(11):2654-61. 摘要

33. Owen RG, Barrans SL, Richards SJ, et al. Waldenström macroglobulinemia: development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001 Sep;116(3):420-8.全文  摘要

34. Giné E, Rovira J, Martinez-Trillos, et al. Initial features and outcome are similar in patients with lymphoplasmacytic lymphoma regardless they meet or not criteria of Waldenström macroglobulinemia. Blood (ASH Annual Meeting Abstracts). 2011;118:3677.全文

35. Banwait R, O'Regan K, Campigotto F, et al. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol. 2011;86:567-572. 摘要

36. Vitolo U, Ferreri AJ, Montoto S. Lymphoplasmacytic lymphoma-Waldenström's macroglobulinemia. Crit Rev Oncol Hematol. 2008;67:172-185. 摘要

37. Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenström's macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2004:257-282.全文  摘要

38. Berentsen S, Beiske K, Tjønnfjord GE, et al. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology. 2007;12:361-370.全文  摘要

39. Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 2016 Sep 8;128(10):1321-8.全文  摘要

40. Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenström's macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29 (suppl 4):iv41-50. 摘要

41. Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood. 2019 Dec 5;134(23):2022-35.全文  摘要

42. Buske C, Sadullah S, Kastritis E, et al. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018 Jul;5(7):e299-309. 摘要

43. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004 Dec 1;101(11):2593-8.全文  摘要

44. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25:3344-3349.全文  摘要

45. Kastritis E, Gavriatopoulou M, Kyrtsonis MC, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. Blood. 2015 Sep 10;126(11):1392-4.全文  摘要

46. Rummel MJ, Niederle N, Maschmeyer G, et al; Study Group Indolent Lymphomas. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203-1210. 摘要

47. Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Ann Hematol. 2018 Aug;97(8):1417-25. 摘要

48. Laribi K, Poulain S, Willems L, et al. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients: a study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2019 Jul;186(1):146-9.全文  摘要

49. Fung M, Jacobsen E, Freedman A, et al. Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine. Clin Infect Dis. 2019 Jan 7;68(2):247-55.全文  摘要

50. Gavriatopoulou M, García-Sanz R, Kastritis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017 Jan 26;129(4):456-9.全文  摘要

51. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27:3830-3835. 摘要

52. Dimopoulos MA, Chen C, Kastritis E, et al. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):110-7. 摘要

53. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström macroglobulinemia. Am J Hematol. 2010 Sep;85(9):670-4.全文  摘要

54. Cappuccio JM, Ghobrial IM, Castillo JJ, et al. Long-term follow-up of exceptional responders on the phase II trial of weekly bortezomib and rituximab in untreated and relapsed patients with Waldenstrom's macroglobulinemia. J Clin Oncol. 2016 May 20;34(15 suppl):8065.全文

55. Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia. J Clin Oncol. 2018 Sep 20;36(27):2755-61.全文  摘要

56. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018 Jun 21;378(25):2399-410.全文  摘要

57. Caldeira D, Alves D, Costa J, et al. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One. 2019 Feb 20;14(2):e0211228.全文  摘要

58. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 August – 2 September 2021. Sep 2021 [internet publication].全文

59. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 October 2021. Oct 2021 [internet publication].全文

60. Tang CPS, Lip GYH, McCormack T, et al. Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Br J Haematol. 8 Sep 2021 [Epub ahead of print].全文  摘要

61. Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009 Apr 16;113(16):3673-8.全文  摘要

62. Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer. 2012 Jan 15;118(2):434-43.全文  摘要

63. Stone MJ, Bogen SA. Role of plasmapheresis in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):238-40. 摘要

64. Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28;124(9):1404-11.全文  摘要

65. Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan;160(2):171-6.全文  摘要

66. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Waldenström macroglobulinemia/lymphoplasmacytic lymphoma [internet publication].全文

67. Treon SP, Hanzis C, Manning RJ, et al. Maintenance rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol. 2011;154:357-362. 摘要

68. Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7.全文  摘要

69. Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol. 2017 Sep 1;3(9):1257-65.全文  摘要

70. Treon S, Hunter Z, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinaemia: results of WMCTG trial 03-248. Clin Cancer Res. 2007;13:3320-3325.全文  摘要

71. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 Apr 20;25(12):1570-5.全文  摘要

72. Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb;18(2):241-50. 摘要

73. Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):133-5. 摘要

74. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10;28(8):1422-8.全文  摘要

75. Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:2227-2232. 摘要

76. Kyriakou C, Canals C, Taghipour G, et al. Autologous stem cell transplantation (ASCT) for patients with Waldenstrom's macroglobulinemia: an analysis of 201 cases from the European Bone Marrow Transplant Registry (EBMT). Haematologica. 2007;92(suppl):PO-1228(abstr).

77. Kyriakou C, Canals C, Taghipour G, et al. Allogeneic stem cell transplantation (ALLO-SCT) in Waldenstrom macroglobulinemia (WM): an analysis of 106 cases from the European Bone Marrow Registry (EBMT). Haematologica. 2007;92(suppl):WM3.9(abstr).

78. Kyriakou C, Canals C, Cornelissen JJ, et al. Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010 Nov 20;28(33):4926-34.全文  摘要

79. Cornell RF, Bachanova V, D'Souza A, et al. Allogeneic transplantation for relapsed Waldenström macroglobulinemia and lymphoplasmacytic lymphoma. Biol Blood Marrow Transplant. 2017 Jan;23(1):60-6.全文  摘要

80. Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014;124:503-510.全文  摘要

81. Castillo JJ, Meid K, Gustine JN, et al. Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in Waldenström macroglobulinemia. Clin Cancer Res. 2018 Jul 15;24(14):3247-52.全文  摘要

82. Castillo JJ, Gustine J, Meid K, et al. Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia. Blood. 2018 Nov 29;132(suppl 1):2888.全文

83. Paulus A, Manna A, Akhtar S, et al. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. Br J Haematol. 2018 Oct;183(2):196-211.全文  摘要

84. Vidal-Crespo A, Matas-Céspedes A, Rodriguez V, et al. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica. 2020 Apr;105(4):1032-41.全文  摘要

85. Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. Am J Hematol. 2014;89:237-242. 摘要

86. Treon SP, Meid K, Tripsas C, et al. Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15;23(10):2400-4.全文  摘要

87. Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström's macroglobulinemia. Clin Cancer Res. 2010;16:1033-1041.全文  摘要

88. Ghobrial IM, Leleu X, Azab AK, et al. Novel therapeutic agents in Waldenstrom's macroglobulinaemia. Clin Lymphoma Myeloma. 2009;9:84-86. 摘要

89. Ghobrial IM, Campigotto F, Murphy TJ, et al. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood. 2013 Feb 21;121(8):1296-303.全文  摘要

90. Furman RR, Eradat H, DiRienzo CG, et al. A phase II trial of ofatumumab in subjects with Waldenstrom's macroglobulinemia. Blood. 2011;118:3701.全文

91. Herth I, Hensel M, Rieger M, et al. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia. Leuk Lymphoma. Leuk Lymphoma. 2015;56:97-102. 摘要

92. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood. 2009;113:4163-4170.全文  摘要

93. Randen U, Trøen G, Tierens A, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014 Mar;99(3):497-504.全文  摘要

94. Schollkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006;47:253-260. 摘要

95. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27:250-255. 摘要

96. Kyle RA, Greipp PR, Gertz MA, et al. Waldenström's macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000;108:737-742.全文  摘要

97. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenström's macroglobulinaemia with bortezomib. Haematologica. 2005;90:1655-1658.全文  摘要

98. Baldini L, Nobile-Orazio E, Guffanti A, et al. Peripheral neuropathy in IgM monoclonal gammopathy and Waldenstrom's macroglobulinemia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. Am J Hematol. 1994;45:25-31. 摘要

内容使用需遵循免责声明